You are here

Multifunctional Antisense Therapeutics Nanocarrier and Inhalation Device

Award Information
Agency: Department of Defense
Branch: Office for Chemical and Biological Defense
Contract: HDTRA1-10-P-0040
Agency Tracking Number: C101-102-0011
Amount: $99,982.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: CBD10-102
Solicitation Number: 2010.1
Solicitation Year: 2010
Award Year: 2010
Award Start Date (Proposal Award Date): 2010-05-17
Award End Date (Contract End Date): 2010-11-16
Small Business Information
Photonic Systems Division 20600 Gramercy Place, Bldg. 100
Torrance, CA 90501
United States
DUNS: 153865951
HUBZone Owned: No
Woman Owned: Yes
Socially and Economically Disadvantaged: No
Principal Investigator
 Gregory Zeltser
 Principal Scientist
 (310) 320-3088
Business Contact
 Gordon Drew
Title: Chief Financial Officer
Phone: (310) 320-3088
Research Institution

To address the CBD need for improved formulations to enhance the ease of use and bioavailability of antisense therapeutics, Physical Optics Corporation (POC) proposes to develop a Multifunctional Antisense Therapeutics Nanocarrier and Inhalation Device (MATEN). This proposed system is based on a new dry powder formulation and a novel design of an inhaler that uses in-house developed mature components. POC’s innovations in the nanocarrier (NC) construct and in the design of the inhaler, which is capable of delivering a single dose from the MATEN during one deep and slow inspiration, will enhance the bioavailability for antisense therapeutics that is necessary for the prophylaxes and early treatment of warfighters against emerging bio-warfare threats. As a result, this technology offers a formulation that is stable at ambient temperature, minimizes the potential for introduction of immunogenic materials and the bulk and complexity of dispensing, and which directly addresses the requirements of the Transformational Medical Technologies Initiative (TMTI) program. In Phase I, POC will demonstrate the feasibility of the MATEN by demonstrating product stability and establishing enhanced bioavailability in an animal model. In Phase II, POC will optimize candidate formulation for maximum bioavailability and conduct initial pharmacokinetic and pharmacodynamic studies in an animal model.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government